IT
IntraGel Therapeutics, Ltd.
Israel · Biotech
IntraGel Therapeutics develops SRGel, a solvent-free injectable formulation designed to release drugs gradually from a single administration.
Product and customers
Its TumoCure candidate combines the platform with cisplatin for direct injection into solid tumors, aiming to maintain local drug exposure while limiting systemic effects. The company is advancing this localized delivery approach through clinical development for head-and-neck cancer and broader formulation applications.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Strategic investment | $7M | UroGen Pharma Ltd. — Participant |